English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Vilazodone HCl (VLN) is chemically 5-(4-[4-(5-cyano-1Hindol-3-yl) butyl] piperazin-1-yl) benzofuran-2-carboxamide hydrochloride [1] (Figure 1). It contains an indole piperazine that utilizes its function as an SSRI and 5-HT1a receptor partial agonist [2]. It belongs to the category of serotonergic antidepressant approved by FDA (Food and Drug Administration) for treatment of depressive disorder [3]. It is a serotonin reuptake inhibitor and serotonin 1A receptor partial agonist having strong affinity for D2 dopaminergic receptors [4]. It has actions at several 5-HT (serotonin) receptor subtypes. The extensive literature Abstract

Development and Validation of Vilazodone HCl by RP-HPLC In Bulk and in Pharmaceutical Formulation Along with its Application in Dissolution